ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,214.08
0.51%
US Tech 100
17,662.00
0.34%
다우존스 지수
39,387.76
0.85%
Bitcoin
62,457.04
2.07%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) 뉴스

INMB

INmune Bio (INMB)

INmune Bio Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:INMB
일자시간출처헤드라인심볼기업
2024/05/1005:05GlobeNewswire Inc.INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
2024/05/0721:00GlobeNewswire Inc.INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9NASDAQ:INMBINmune Bio Inc
2024/04/3021:00GlobeNewswire Inc.INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsNASDAQ:INMBINmune Bio Inc
2024/04/2921:00GlobeNewswire Inc.INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
2024/04/2522:00GlobeNewswire Inc.INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:INMBINmune Bio Inc
2024/04/2321:00GlobeNewswire Inc.INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayNASDAQ:INMBINmune Bio Inc
2024/04/2221:00GlobeNewswire Inc.INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingNASDAQ:INMBINmune Bio Inc
2024/04/0821:00GlobeNewswire Inc.INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024NASDAQ:INMBINmune Bio Inc
2024/03/2905:01GlobeNewswire Inc.INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateNASDAQ:INMBINmune Bio Inc
2024/03/2705:01GlobeNewswire Inc.INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28NASDAQ:INMBINmune Bio Inc
2024/03/1321:00GlobeNewswire Inc.INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyNASDAQ:INMBINmune Bio Inc
2024/03/0522:00GlobeNewswire Inc.INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™NASDAQ:INMBINmune Bio Inc
2024/02/1223:00GlobeNewswire Inc.INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INMBINmune Bio Inc
2024/02/0623:00GlobeNewswire Inc.INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024NASDAQ:INMBINmune Bio Inc
2024/01/3022:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2024/01/3022:00GlobeNewswire Inc.INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease ProgramNASDAQ:INMBINmune Bio Inc
2024/01/1622:30GlobeNewswire Inc.ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:INMBINmune Bio Inc
2024/01/0306:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2024/01/0222:00GlobeNewswire Inc.INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
2023/12/1906:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2023/12/1906:05Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:INMBINmune Bio Inc
2023/12/1906:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2023/12/1906:01GlobeNewswire Inc.INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDANASDAQ:INMBINmune Bio Inc
2023/11/3006:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2023/11/2922:00GlobeNewswire Inc.INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumNASDAQ:INMBINmune Bio Inc
2023/11/2806:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2023/11/2722:00GlobeNewswire Inc.INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s DiseaseNASDAQ:INMBINmune Bio Inc
2023/11/1606:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
2023/11/1523:00GlobeNewswire Inc.INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in EuropeNASDAQ:INMBINmune Bio Inc
2023/11/1401:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
 검색 관련기사 보기:NASDAQ:INMB

최근 히스토리

PM
XAUUSD
Gold vs US Dollar
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
NYSE
JPM
JP Morgan Chase
CCOM
US30
US 30
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
AMEX
SPY
SPDR S&P 500
NYSE
DIS
Walt Disney
NYSE
CVX
Chevron
CCOM
SILVER
SILVER
CCOM
US100
US Tech 100
NASDAQ
AMZN
Amazon.com
CCOM
US500
US 500
NYSE
VZ
Verizon Communications
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유